New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:00 EDTCVS, SPW, RJF, GFIG, DVA, TER, WBMD, R, MRO, HST, OFC, ESV, SNY, RDS.A, ITG, EVR, ADBE, BSXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Adobe (ADBE) upgraded to Outperform from Underperform at JMP Securities... Corporate Office Properties (OFC) upgraded to Neutral from Sell at Citigroup... DaVita (DVA) upgraded to Buy from Neutral at Nomura... Evercore Partners (EVR) upgraded to Outperform from Market Perform at Keefe Bruyette... GFI Group (GFIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Host Hotels (HST) upgraded to Buy from Neutral at Citigroup... ITG (ITG) upgraded to Outperform from Market Perform at Keefe Bruyette... Marathon Oil (MRO) upgraded to Buy from Neutral at Goldman... Raymond James (RJF) upgraded to Outperform from Market Perform at Keefe Bruyette... Royal Dutch Shell (RDS.A) upgraded to Outperform from Neutral at Credit Suisse... Ryder (R) upgraded to Top Pick from Outperform at RBC Capital... SPX Corp. (SPW) upgraded to Buy from Neutral at Nomura... Sanofi (SNY) upgraded to Buy from Hold at Jefferies... WebMD (WBMD) upgraded to Market Perform from Underperform at Raymond James... CVS Caremark (CVS) upgraded to Outperform from Neutral at Macquarie... Ensco (ESV) upgraded to Buy from Hold at Jefferies... Teradyne (TER) upgraded to Outperform from Sector Perform at Pacific Crest... Boston Scientific (BSX) upgraded to Overweight from Underweight at Barclays.
News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
07:21 EDTCVSUBS to hold a conference
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
May 19, 2015
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
07:17 EDTCVSCVS Health has a conference call hosted by JPMorgan
JPMorgan Analyst Gill will host a conference call with CEO Larry Merlo on May 21 at 11 am.
06:55 EDTSNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
13:48 EDTESVEnsco reports departure of chairman Dan Rabun
Subscribe for More Information
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
07:19 EDTSPWElectric Products Group to hold a conference
EPG 2015 is being held in Longboat Key, Florida on May 18-20 with webcasted company presentations to begin on May 18 at 7:30 am; not all company presentations may be webcasted. Webcast Link
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
17:39 EDTSPWRelational Investors gives quarterly update on stakes
Subscribe for More Information
10:29 EDTSNY, BSXAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBSXAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use